Antiangiogenic activities of bemiparin sodium, enoxaparin sodium, nadroparin calcium and tinzaparin sodium

Doǧan, Ömer Tamer; Polat, Zübeyde Akın; Karahan, Oğuz; Epöztürk, Kürşat; Altun, Ahmet; Akkurt, İbrahim; Çetin, Ali

doi:10.1016/j.thromres.2011.05.005

Cited by 26 publications

(27 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Chemical β-elimination depolymerization 3.500 (Depasse et al, 2003;Dogan et al, 2011;Jeske et al, 2011;Perez-Ruiz et al, 2002;Vignoli et al, 2011;Westmuckett et al, 2001) (Vignoli et al, 2011) These advantages have led to their increasing use in the treatment of cancer as angiogenesis inhibitors. Clinical studies suggest a significant mortality reduction in cancer patients receiving different heparin fractions for the treatment of venous thromboembolism versus those receiving UFH (Akl et al, 2008).…”

Section: Bemiparin Badyketmentioning

confidence: 99%

“…Moreover, tissue factor (TF) and its natural inhibitor (TFPI) are also important heparin-binding proteins that perform well-recognized roles in the regulation of angiogenesis, tumor growth and metastasis (Bobek & Kobarik, 2004;Borsig, 2010;Debergh et al, 2010;Norrby, 2006). LMWH may influence angiogenesis through modulation of the expression of angiogenic growth factors (VEGF and bFGF) and their inhibitors (Dogan et al, 2011;Gasowska et al, 2009;Mousa & Petersen, 2009). LMWH can be classified according to their molecular weight into first generation and second generation, as show in table 1 (Hirsh et al, 2001;Vignoli et al, 2011).…”

Section: Bemiparin Badyketmentioning

confidence: 99%

“…In this sense, it is important to emphasize that the anticoagulant properties of heparins are related to chain length, as reflected by the increased anti-Xa/anti-IIa activity of LMWHs ( Figure 3) (Bobek & Kovarik, 2004;Grande & Caparro, 2005;Hirsh et al, 2001). Other authors demonstrated that 7 heparin fragments with less than 18 saccharides hinder the activity of VEGF and those with less than 10 saccharides reduce bFGF activity (Bobek & Kovarik, 2004;Debergh et al, 2010;Dogan et al, 2011). Debergh et al studied the effects of nadroparin (Fraxiparin, 4.5 kDa) on tumor-associated angiogenesis, using a dorsal skinfold window chamber model in the Syrian hamster.…”

Section: First Generation Heparinsmentioning

confidence: 99%

“…The comparison of the properties of first and second generation heparins is shown in Figure 3 (Norrby, 2006). Bemiparin (Badyket, 3.5 kDa) (Balibrea et al, 2007;Dogan et al, 2011;Jeske et al, 2011;Vignoli et al, 2011) has been available in Europe for 10 years but only recently has been evaluated in clinical trials to determine its angionenic potential in patients with cancer. The efficacy of bemiparin administration in patients limited small cell lung cancer was evaluated in the ABEL study.…”

Section: Second Generation Heparinsmentioning

confidence: 99%

“…Moreover, nadroparin and tinzaparin have also substantial antiangiogenic effects at the moderate concentration of 10 IU/10 µl as a result of their higher antiangiogenic potential. A possible categorization of LMWHs in this context would facilitate the choice of drug that would be used in further experimental and clinical research (Dogan et al, 2011). Actually, new ULMWHs are investigated as semuloparin (2.5 kDa) with a half-life of 16-20 hours that allows one daily subcutaneous injection.…”

Section: Second Generation Heparinsmentioning

confidence: 99%

See 4 more Smart Citations

Heparin-Like Drugs with Antiangiogenic Activity

Aguilar¹,

García‐Fernández²,

Palao-Suay³

et al. 2012

Tumor Angiogenesis

View full text Add to dashboard Cite

Section: Bemiparin Badyketmentioning

confidence: 99%

Section: Bemiparin Badyketmentioning

confidence: 99%

Section: First Generation Heparinsmentioning

confidence: 99%

Section: Second Generation Heparinsmentioning

confidence: 99%

Section: Second Generation Heparinsmentioning

confidence: 99%

See 3 more Smart Citations

Heparin-Like Drugs with Antiangiogenic Activity

Aguilar¹,

García‐Fernández²,

Palao-Suay³

et al. 2012

Tumor Angiogenesis

View full text Add to dashboard Cite

Factor-Xa inhibitors protect against systemic oxidant damage induced by peripheral-ischemia reperfusion

Çalışkan

Yavuz

Karahan

et al. 2013

J Thromb Thrombolysis

View full text Add to dashboard Cite

Factor-Xa inhibitors are often used for prophylaxis and for the treatment of thrombotic vascular disorders. However, it is not known whether they are beneficial during the recanalization of the thrombotic vascular segment and during tissue reperfusion. Herein, we describe an animal study that was designed to investigate the possible protective effects and antioxidant properties of factor-Xa inhibitors. Forty rats were included in the study and were randomly divided into five equal groups. The first group served as a control group from which we obtained basal oxidant and antioxidant parameters. Peripheral ischemia was induced in the second group (sham group) for 6 h, and plasma levels of nitrogen oxide (NOx), prolidase and malondialdehyde (MDA) were obtained after 30 min of reperfusion. The sham group did not receive any drugs. Oral rivaroxaban (3 mg/kg) was administrated to Group III, intraperitoneal enoxaparin sodium (250 U/kg) was administrated to Group IV, and intraperitoneal bemiparine sodium (250 U/kg) was administrated to Group V 1 week prior to the induction of peripheral ischemia (for 6 h)-reperfusion. After 30 min of reperfusion, blood samples were obtained and NOx, prolidase and MDA levels in these groups were detected, and the rats were sacrificed. NOx levels were statistically similar (p > 0.05) between Groups I, II, III, IV, and V (20.7 ± 10.4, 17.4 ± 9.7, 25.9 ± 24.2, 27.0 ± 11.9, 23.3 ± 17.3 μmol/L, respectively). MDA levels were significantly lower (p < 0.05) in Groups III (rivaroxaban), IV (enoxaparin sodium), and V (bemiparine sodium) (24.9 ± 11.9, 25.9 ± 4.4, 25.4 ± 10.8 μmol/L, respectively) when compared with the sham group (Group II) (75.6 ± 24.3 μmol/L). Prolidase levels were higher (p > 0.05) in the ischemia reperfusion groups (659.2 ± 130.6 in II (sham), 1,741.0 ± 1,530.6 in III (rivaroxaban), 2,453.8 ± 1,590.4 in IV (enoxaparin sodium), and 889.2 ± 574.7 U/g in V (bemiparine sodium) than in the control group (144.6 ± 131.8 U/g). Ischemia-reperfusion events may occur in prothrombotic disorders. During these events, prophylactic or therapeutic factor-Xa inhibitors can protect against thrombosis and oxidative reperfusion injury. The new oral factor-Xa inhibitor, rivaroxaban, appears to provide the same antioxidant support as injectable low molecular weight heparins (LMWHs).

show abstract